Repetitive Transcranial Magnetic Stimulation in Youth With Treatment Resistant Major Depression
Bibliographic Data
| ID | 15526899 |
|---|---|
| Authors | Frank P Macmaster (0000-0002-7159-7583, Alberta Health, corresponding author), Paul E Croarkin (0000-0001-6843-6503, Mayo Clinic), T Christopher Wilkes (University of Calgary), Quinn McLellan (0000-0003-3806-2218, University of Calgary), Lisa Marie Langevin (0000-0002-0324-6415, University of Calgary), Natalia Jaworska (0000-0001-5643-8210, University of Ottawa), Rose Swansburg (0000-0003-0679-6380, University of Calgary), Rose M Swansburg, Yamile Jasaui (University of Calgary), Ephrem Zewdie (0000-0003-1206-2471, University of Calgary), Patrick Ciechanski (University of Calgary), Adam Kirton (0000-0001-5209-3374, University of Calgary) |
| Year | 2019 |
| Volume | 10 |
| Pages | 170-170 |
| Publication date | 2019-03-29 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2019.00170 |
| PMID | 30984044 |
| OpenAlex | W2931585635 |
| Language | EN |
| Citations received | 4 |
| References cited | 27 |
Background: Major depressive disorder (MDD) is common in youth and treatment options are limited. We evaluated the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in adolescents and transitional aged youth with treatment resistant MDD. Methods: Thirty-two outpatients with moderate to severe, treatment-resistant MDD, aged 13-21 years underwent a three-week, open-label, single center trial of rTMS (ClinicalTrials.gov identifier NCT01731678). rTMS was applied to the left dorsolateral prefrontal cortex (DLPFC) using neuronavigation and administered for 15 consecutive week days (120% rest motor threshold; 40 pulses over 4 s [10 Hz]; inter-train interval, 26 s; 75 trains; 3,000 pulses). The primary outcome measure was change in the Hamilton Depression Rating Scale (Ham-D). Treatment response was defined as a >50% reduction in Ham-D scores. Safety and tolerability were also examined. Results: rTMS was effective in reducing MDD symptom severity ( t = 8.94, df = 31, p Conclusions: Our single center, open trial suggests that rTMS is a safe and effective treatment for youth with treatment resistant MDD. Larger randomized controlled trials are needed. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT01731678
Adverse effect · Deep transcranial magnetic stimulation · Depression (economics · Major depressive disorder · Mood · Physical therapy · Psychiatry · Randomized controlled trial · Stimulation · Tolerability · Transcranial magnetic stimulation · Treatment-resistant depression · Medicine · Pain Management and Treatment · Psychology · Psychosomatic Disorders and Their Treatments · Transcranial Magnetic Stimulation Studies · Internal Medicine
| Citations per year | 0.67 |
|---|---|
| Citation span | 2020 - 2025 (6) |
| Highly cited | No |